Apnimed (NASDAQ: APMD) recently received a number of ratings updates from brokerages and research firms:
- 8/26/2026 – Apnimed was upgraded by Zacks Research to “hold”.
- 8/25/2026 – Apnimed is now covered by Evercore Inc. They set an “outperform” rating on the stock.
- 8/25/2026 – Apnimed is now covered by Lifesci Capital. They set an “outperform” rating and a $50.00 price target on the stock.
- 8/25/2026 – Apnimed is now covered by Bank of America Corporation. They set a “buy” rating and a $41.00 price target on the stock.
- 8/25/2026 – Apnimed is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $60.00 price target on the stock.
- 8/8/2026 – Apnimed was upgraded by Wall Street Zen to “hold”.
Insider Buying and Selling at Apnimed
In other Apnimed news, major shareholder Morningside Venture Investment acquired 312,500 shares of the stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the purchase, the insider directly owned 7,152,713 shares of the company’s stock, valued at approximately $114,443,408. This trade represents a 4.57% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.
Read More
- Five stocks we like better than Apnimed
- TSMC Revenue Jumps 53% in August, Signaling Strong AI Chip Demand
- This AI ETF Is Missing the Biggest AI Winners
- Could Snowflake’s Big Quarter Be a Sign of More to Come?
- Microsoft’s Azure Reporting Shift Adds Clarity, But the Bull Case Came First
Receive News & Ratings for Apnimed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed Inc and related companies with MarketBeat.com's FREE daily email newsletter.
